"Johnson and Johnson Pricing Strategy - PDF"
Brochure More information from http://www.researchandmarkets.com/reports/298299/ Pharmaceutical Pricing Strategies: Price optimization, reimbursement and regulation in Europe, US and Japan Description: Maximizing prices and securing reimbursement status for a product is increasing in importance, as pharmaceutical companies seek to ensure that they achieve a high return on investment from current and future drugs in light of a sustained R&D productivity shortfall and a wave of impending blockbuster patent expiries. Pharmaceutical Pricing Strategies: Price optimization, reimbursement and regulation in Europe, US and Japan, is a report which will help you create an effective pricing policy, in the midst of continued regulatory uncertainty, stagnant R&D and the continued cost-containment efforts of healthcare payors. This report will provide detailed analysis of the key issues and market environments making up the pricing landscape, and enable you to conduct pricing and reimbursement evaluations for products throughout the development lifecycle. Gain a detailed understanding a drug's potential price profile and optimize future returns by including these assessments in portfolio evaluations and lifecycle planning, with the help of this report. Key findings of the report - Over the next five years, the most likely pricing scenario in Europe will see the impact of pharmacoeconomics, parallel trade and generic substitution continue to increase gradually. The accession of 10 new countries to the EU will have a small, but negative, effect on prices throughout the EU-15. - Over the next five years, the most likely pricing scenario prevailing in Japan will involve a continuation of the current reimbursement reform led by biennial price-cutting. By weighting the cuts against generic and 'me-too' products, innovative products can still continue to receive premium prices, while the overall drugs bill is reduced. - To maximize return from drug development investment, companies need to ensure the evidence that demonstrates product value and supports the case for reimbursement, is strongly and effectively communicated in the decision- making process. - The pricing of a reformulation relative to other formulations, can be divisive in dictating the success of reformulation strategies. To achieve growth, manufacturers must often strike a balance between the premium pricing of reformulations and ensuring that pricing remains competitive and does not restrict volume driven growth. Key questions answered in this report - What are the major issues currently impacting on pharmaceutical pricing? - How will the key trends in pharmaceutical R&D productivity and healthcare spend affect pharmaceutical pricing strategies? - What impact will Medicare reform have on the US pricing of drugs for seniors? - What are the current pricing regulations and associated issues in the major pharma markets including North America, Europe and Asia Pacific? - How will EU accession impact on pricing, parallel imports and generic competition in EU's major market? - What are the likely future developments in pricing in the major pharma markets including North America, Europe and Japan? - What can be done to maximize returns through applying different pricing strategies across the drug lifecycle? Top five reasons to order your copy today 1.) Plan an optimum pricing strategy using forecasts of different pricing scenarios in major markets (including the US, Japan and Europe). 2.) Compare and contrast different pricing and reimbursement environments in key markets including the US, Japan, France, Germany, Italy, Spain, the UK, Canada, Australia and China. 3.) Optimize return on investment across the drug lifecycle by understanding the implications of using different pricing strategies at various stages in the product lifecycle. 4.) Measure the impact of health economics, parallel imports and generic substitution on pricing in major markets including the US, Japan, France, Germany, Italy, Spain and the UK. 5.) Benchmark a variety of different case studies outlining the use of different pricing strategies by different companies, for different drugs, in different pricing environments. Contents: Pharmaceutical pricing strategies Executive Summary The importance of price optimization Pricing and reimbursement in North America Pricing and reimbursement in Europe Pricing and reimbursement in Japan and the rest of the world Pricing strategies for new drugs Pricing strategies for established drugs Chapter 1 The importance of price optimization Summary Introduction Maximizing return on investment R&D productivity shortfall Key patent expiries Healthcare cost containment Cost-containment initiatives Cost containment in pharmaceutical expenditure Key issues Price optimization Reimbursement regulations Reference pricing Pharmacoeconomic evaluations Parallel imports Generic substitution Hot topics US reimportation Medicare Drug Benefit EU enlargement Price harmonization Pricing and reimbursement hurdles Chapter 2 Pricing and reimbursement in North America Summary Introduction US pricing regulations Medicare Medicaid Private healthcare Recent developments in the US The 2003 Medicare Prescription Drug Act Expanded access… Improved drug compliance… Higher utilization… Price comparison tool… Medicare drug benefit formularies… Medicaid budget crisis Price controls in Maine? Florida's Medicaid drug rebates Pharmacoeconomics in the US Pharmacoeconomics in public healthcare provision Pharmacoeconomics in private healthcare provision Managed care pharmacoeconomic submissions Future use of pharmacoeconomics in the US Parallel imports in the US Developments in cross-border trade Reimportation task force report… State-level action… Generic substitution in the US The Waxman-Hatch Act Pediatric exclusivity provisions Anti-competition agreements Delaying tactics and 180-day exclusivity Biogenerics Trends in generic usage 'March-in' law… Future pricing scenarios in the US Best case pricing scenario Worst case pricing scenario Most likely pricing scenario Canadian pricing regulations Federal measures Provincial measures Driving down prices Reimportation Chapter 3 Pricing and reimbursement in Europe Summary Introduction European pricing regulations France Recent developments… Germany Recent developments… Italy Recent developments… Spain Recent developments… The UK Recent developments… Pharmacoeconomics in Europe France Germany Italy Spain UK Parallel importing in Europe Penetration of parallel imports Price differentials… Initiatives to encourage use of parallel imports… Ability to obtain a license to import products… Regulations and key legal decisions Merck versus Stephar… Bayer (Adalat)… Bristol-Myers Squibb versus Paranova… The Silhouette case… The Maglite case… The Davidoff case… Recent developments GSK's supply restriction in Greece… Lack of regulatory framework in France… Novo Nordisk's supply of Actrapid Novolet in Spain… Pfizer's direct distribution to pharmacies in Spain… Generic substitution in Europe The mutual recognition procedure Future changes in European generics legislation Government initiatives encouraging generic uptake EU accession Drug pricing policies and reimbursement post-accession Parallel trade post-accession Generics post-accession Future pricing scenarios in Europe Best case pricing scenario Worst case pricing scenario Most likely pricing scenario Chapter 4 Pricing and reimbursement in Japan and the rest of the world Summary Introduction Japanese pricing regulations Recent developments Pharmacoeconomics in Japan Parallel importing in Japan Generic substitution in Japan Future pricing scenarios in Japan Best case pricing scenario Worst case pricing scenario Most likely pricing scenario Australian pricing regulations Benchmark pricing Cost plus method Average monthly treatment cost Prices for new items Chinese pricing regulations Chapter 5 Pricing strategies for new drugs Summary Introduction Pricing strategies in early-stage development Therapy area analysis Epidemiology analysis Treatment delivery analysis Market needs analysis Pricing analysis Cost analysis Economic analysis Decision-maker analysis Market research Initial assessment of drug candidates Pricing strategies in mid stage development Evaluating opportunities Case study: Aventis appeal against NICE… Improving product value Case study: Johnson & Johnson's Concerta… Pricing strategies in late stage development Sub-population analysis Choosing outcomes Case study: Merck's Zocor (simvastatin)… Patient reported outcomes Case study: Pfizer's Viagra… Head-to-head trials Phase III pharmacoeconomic studies Phase IV studies Pricing strategies for new product approvals Submission dossiers Identifying key decision makers Failure to secure reimbursement Working with decision makers… Case study – Eli Lilly's Xigris… Applying pressure through lobbying… Case study – Amgen's Aranesp… Brokering deals… Case study – Celebrex in France… External support EU launch order First choice countries… Second choice countries… Third choice countries… Fourth choice countries… Global price optimization Chapter 6 Pricing strategies for established drugs Summary Introduction Strategic pricing of reformulations Benchmarking relative pricing Patient expansion strategies Patient switching and generic defence strategies Generic defence reformulations Strategic pricing at patent expiry US patent expiry European patent expiry Chapter 7 Appendix Glossary Sources y Ordering: Order Online - http://www.researchandmarkets.com/reports/298299/ Order by Fax - using the form below Order by Post - print the order form below and sent to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607- 1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/ Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Pharmaceutical Pricing Strategies: Price optimization, reimbursement and regulation in Europe, US and Japan Web Address: http://www.researchandmarkets.com/reports/298299/ Office Code: OC8HOOPMUNNRP Product Formats Please select the product formats and quantity you require: Quantity Hard Copy - : EURO €2,054.00 + Euro €50 Shipping/Handling * Electronic - : EURO €1,989.00 * Shipping/Handling is only charged once per order. Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Email Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL) Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: American Express Diners Club Master Card Visa Cardholder's Name Cardholder's Signature Expiry Date Card Number CVV Number Issue Date (for Diners Club only) Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Please transfer funds to: Pay by wire transfer: Account number 833 130 83 Sort code 98-53-30 Swift code ULSBIE2D IBAN number IE78ULSB98533083313083 Bank Address Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646) 607-1907 or (646) 964-6609 - From USA +353 1 481 1716 or +353 1 653 1571 - From Rest of World